A Phase 2a, open-label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD)

    Project: Other project

    Project Details

    StatusActive
    Effective start/end date6/6/226/5/27